Drugs / C16G2
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 26 trials | ||||||
| Phase 2 | NCT03196219 | Jul → Nov 2017 | dental caries | Armata Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03052842 | Feb → Apr 2017 | dental caries | Armata Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02594254 | Nov 2015 → Jun 2016 | dental caries | Armata Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02509845 | Jul 2015 → Feb 2016 | dental caries | Armata Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02254993 | Oct 2014 → Jun 2015 | dental caries | Armata Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02044081 | Feb → Jul 2014 | dental caries | Armata Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03004365 Comparator | Jan → Mar 2017 | dental caries | Armata Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C16G2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03004365 ↗ |
| Known as | STAMP C16G2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297712 ↗ |
| Modality | Peptide | “antimicrobial peptide” NCT02254993 ↗ |
| Route | Oral | “Administered in multiple oral gel and/or mouth rinse doses” NCT02044081 ↗ |